Incannex Healthcare Limited

General Information

(Note: This is NOT an IPO.  IPOScoop has No Call on this offering because it is NOT an IPO. This is an uplift offering of American Depositary Shares (ADS) on the NASDAQ under the proposed symbol “IXHL.” The company’s ordinary shares already trade on the Australian Securities Exchange under the symbol “IHL”. Each ADS represents 50 ordinary shares.)

We are a clinical stage pharmaceutical development company and the success of our drug candidates is therefore uncertain. We focus on medicinal synthetic cannabidiol pharmaceutical products and psychedelic medicine therapies. 

We are developing targeted and scientifically validated fixed-dose combinations of synthetic cannabidiol and psychedelic agents. We focus on clinical indications that we believe represent unmet or inadequately addressed medical needs and also represent compelling commercial opportunities. In particular, we are developing three unique pharmaceutical compositions to target five indications: obstructive sleep apnea (“OSA”), traumatic brain injury (“TBI”)/concussion, rheumatoid arthritis, inflammatory bowel disease and inflammatory lung conditions (“ARDS”, “COPD”, Asthma, Bronchitis). We are also developing a treatment for generalized anxiety disorder (“GAD”) utilizing psilocybin combined with innovative psychotherapy methods. We are pursuing FDA registration and marketing approval for each product and therapy under development. 

Note: Revenue and net loss figures are for the 12 months that ended Dec. 31, 2020, and these figures have been converted to U.S. dollars – as shown here – from Australian dollars in the prospectus.


Employees: 4
Founded: 2001
Contact Information
Address Suite 15, Level 12, 401 Docklands Drive Docklands 3008, Victoria Australia
Phone Number + 61 409 840 786
Web Address
View Prospectus: Incannex Healthcare Limited
Financial Information
Market Cap
Revenues $0.96 mil (last 12 months)
Net Income $-3.77 mil (last 12 months)
IPO Profile
Symbol IXHL
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $25.0 mil
Manager / Joint Managers Roth Capital Partners
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change